What's Potentially Driving Boxer, Astral and Santam This July

The JSE opened July at R101 936.15 on the Top 40 Share Index, down 16% from the R121 329.63 high it hit in March, as the gold/PGM-led rally cooled and GDP growth stayed below 1%. The rand is holding a tight R16.34 - R16.66 band, currently sitting around R16.40. Beyond the index, three company-specific news events this past month are doing more to move these three shares than the macro pullback: a R4.7 billion share sale at Boxer (BOX), a first-in-industry vaccine approval at Astral Foods (ARL), and a fresh round of storm claims at Santam (SNT).

Boxer

Latest news: Parent company Pick n Pay (PIK) sold down 12.5% of Boxer's shares in an accelerated bookbuild in May 2026, raising R4.7 billion at R82 per share. That cut Pick n Pay's stake from 65.6% to 53.1%. The proceeds are funding Pick n Pay's own store-revamp turnaround, not Boxer's balance sheet, but the sale materially increased Boxer's free float and trading liquidity. And Pick n Pay has said it won't cut its stake below 50%, capping how much further overhang there is from more parent selling.

Boxer is trading around R82.89, just above the R82 price of May's share placement. That values the company at roughly R38.9 billion, on a P/E of 24.18. This month's scenario points to a possible +7.35% move, toward about R88.98. The business itself is growing, with 2026 revenue up 9.6% to R47.14 billion, profit up 13% to R1.56bn, and the June trading update showed turnover up 12.1%, with new stores doing most of that work. The main risk isn't demand, it's cost. Boxer runs its own delivery fleet, so rising diesel and logistics prices hit margins directly, and management has already flagged this as a risk for next year.

Astral Foods

Latest news: Astral became the first South African poultry producer authorised to begin vaccinating against highly pathogenic avian influenza, starting with broiler breeders in Gauteng. It's being done under strict conditions, with vet supervision, audited vaccine storage, weekly field virus strain monitoring, and full traceability of vaccinated birds' offspring, but gives Astral a biosecurity head start over peers still relying on culling as their only defence against outbreaks that have repeatedly hit the sector.

Astral shares are trading around R237.35, valuing the company at about R9.7 billion. This month's scenario points to a possible +8.5% move, toward about R257.50. Profit jumped sharply because chicken feed (maize) got a lot cheaper, falling from over R5 000 per ton to around R3 400, while chicken prices stayed steady. That combination pushed operating profit up 348% and earnings per share up 467% in the first half of the year. The risk is this could reverse quickly. If maize prices climb back above R4 000 a ton, profits would shrink fast, and any bird flu outbreak that spreads faster than the company's new vaccine programme remains a threat to the whole industry.

Santam 

Latest news: Santam flagged approximately R430 million in net claims from flooding in northern South Africa and Western Cape wildfires in Q1 2026, then took a further hit from severe storms and flooding that struck the Western Cape in May 2026, significant enough for the group to call it out specifically in its interim update. Despite that, Santam said its net underwriting margin held above the midpoint of its 5% - 10% target range through the period, which is the detail the market is watching most closely.

Santam shares recently traded around R389.70. This month's scenario points to a possible +9% move, toward roughly R424.96, which would still sit below the average analyst price target of R481, suggesting there may be room for further gains even after that move. The business itself looks solid. In 2025, Santam's underwriting margin, the profit it keeps after paying out claims, came in at 11.3%, beating its own target range, and premium income grew 10%, with its international business growing even faster, up 25%. The main risk is the weather. More storm damage over winter would test whether the company can keep that margin up, and not everyone agrees on the share price; most analysts rate it a buy, but at least one recommends selling.

Disclaimer:
*Any opinions, views, analysis, or other information provided in this article is provided by BROKSTOCK SA trading as BROKSTOCK as general market commentary and should not be viewed as advice according to the FAIS Act of 2002. BROKSTOCK SA does not warrant the correctness, accuracy, timeliness, reliability, or completeness of any information provided by third parties. You must rely upon your judgement in all aspects of your investment decisions, and all decisions are made at your own risk. BROKSTOCK SA and any of its employees shall not be responsible for and will not accept any liability for any direct or indirect loss, including, without limitation, any loss of profit which may arise directly or indirectly from the use of the market commentary. The content contained within the article is subject to change at any time without notice. BROKSTOCK SA is an authorised financial services provider - FSP No. 51404. T&Cs and Disclaimers are applicable: https://brokstock.co.za/
** This article was prepared by BROKSTOCK analyst Maboko Seabi